- Funding to Date*
Oral diseases are systemic diseases suffered by over 3.5 billion people worldwide: the periodontal disease suffered by half of American adults is linked to diseases such as heart disease, stroke, diabetes and obesity. BrickBuilt Therapeutics is developing a live biological product discovered by CEO Brian Klein. BrickBuilt is using this strain and others in its microbial library to develop microbiome-focused therapeutics for oral and systemic diseases.
This is not a single asset company: BrickBuilt scientists have built a platform to screen the world’s first purpose-built oral microbial culture collection to identify bacterial strains which have therapeutic merit.